UBS Group’s Chimerix, Inc. CMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,901,056
| Closed | -$24.7M | – | 11171 |
|
|
2025
Q1 | $24.7M | Buy |
2,901,056
+2,824,308
| +3,680% | +$15.6M | ﹤0.01% | 2140 |
|
|
2024
Q4 | $267K | Sell |
76,748
-14,636
| -16% | -$20.7K | ﹤0.01% | 6280 |
|
|
2024
Q3 | $85K | Buy |
91,384
+74,024
| +426% | +$66K | ﹤0.01% | 6470 |
|
|
2024
Q2 | $15.2K | Sell |
17,360
-10,881
| -39% | -$10.3K | ﹤0.01% | 7478 |
|
|
2024
Q1 | $29.9K | Sell |
28,241
-16,115
| -36% | -$16.8K | ﹤0.01% | 6742 |
|
|
2023
Q4 | $42.7K | Sell |
44,356
-78,704
| -64% | -$76.2K | ﹤0.01% | 6634 |
|
|
2023
Q3 | $118K | Sell |
123,060
-162,194
| -57% | -$177K | ﹤0.01% | 5720 |
|
|
2023
Q2 | $345K | Buy |
285,254
+90,166
| +46% | +$114K | ﹤0.01% | 5116 |
|
|
2023
Q1 | $246K | Sell |
195,088
-63,693
| -25% | -$104K | ﹤0.01% | 5231 |
|
|
2022
Q4 | $481K | Sell |
258,781
-117,292
| -31% | -$229K | ﹤0.01% | 4744 |
|
|
2022
Q3 | $725K | Buy |
376,073
+307,885
| +452% | +$691K | ﹤0.01% | 4023 |
|
|
2022
Q2 | $142K | Sell |
68,188
-195,104
| -74% | -$627K | ﹤0.01% | 5168 |
|
|
2022
Q1 | $1.21M | Buy |
263,292
+27,482
| +12% | +$153K | ﹤0.01% | 3912 |
|
|
2021
Q4 | $1.52M | Buy |
235,810
+90,997
| +63% | +$546K | ﹤0.01% | 4004 |
|
|
2021
Q3 | $896K | Sell |
144,813
-59,766
| -29% | -$411K | ﹤0.01% | 4284 |
|
|
2021
Q2 | $1.64M | Sell |
204,579
-94,694
| -32% | -$787K | ﹤0.01% | 3753 |
|
|
2021
Q1 | $2.88M | Buy |
299,273
+289,412
| +2,935% | +$2.66M | ﹤0.01% | 3184 |
|
|
2020
Q4 | $48K | Buy |
9,861
+9,285
| +1,612% | +$33.7K | ﹤0.01% | 6230 |
|
|
2020
Q3 | $1K | Sell |
576
-18,217
| -97% | -$53.9K | ﹤0.01% | 7853 |
|
|
2020
Q2 | $58K | Sell |
18,793
-460,295
| -96% | -$1.19M | ﹤0.01% | 5740 |
|
|
2020
Q1 | $690K | Sell |
479,088
-106,523
| -18% | -$186K | ﹤0.01% | 3690 |
|
|
2019
Q4 | $1.19M | Buy |
585,611
+13,833
| +2% | +$25.5K | ﹤0.01% | 4040 |
|
|
2019
Q3 | $1.34M | Buy |
571,778
+25,082
| +5% | +$72.4K | ﹤0.01% | 3693 |
|
|
2019
Q2 | $2.36M | Buy |
546,696
+546,566
| +420,435% | +$1.68M | ﹤0.01% | 2992 |
|
|
2019
Q1 | $0 | Sell |
130
-16,831
| -99% | -$38.3K | ﹤0.01% | 8269 |
|
|
2018
Q4 | $43K | Buy |
16,961
+10,067
| +146% | +$33.7K | ﹤0.01% | 6234 |
|
|
2018
Q3 | $27K | Sell |
6,894
-1,316
| -16% | -$5.6K | ﹤0.01% | 6617 |
|
|
2018
Q2 | $39K | Buy |
8,210
+4,414
| +116% | +$21.1K | ﹤0.01% | 6196 |
|
|
2018
Q1 | $20K | Sell |
3,796
-1,668
| -31% | -$8.45K | ﹤0.01% | 6424 |
|
|
2017
Q4 | $25K | Buy |
5,464
+442
| +9% | +$2.1K | ﹤0.01% | 6387 |
|
|
2017
Q3 | $26K | Buy |
5,022
+94
| +2% | +$463 | ﹤0.01% | 6275 |
|
|
2017
Q2 | $27K | Buy |
4,928
+410
| +9% | +$2.16K | ﹤0.01% | 6083 |
|
|
2017
Q1 | $28K | Sell |
4,518
-8,912
| -66% | -$50.6K | ﹤0.01% | 5919 |
|
|
2016
Q4 | $61K | Buy |
13,430
+9,117
| +211% | +$43K | ﹤0.01% | 5673 |
|
|
2016
Q3 | $24K | Sell |
4,313
-39,566
| -90% | -$181K | ﹤0.01% | 6162 |
|
|
2016
Q2 | $172K | Buy |
43,879
+22,710
| +107% | +$112K | ﹤0.01% | 4638 |
|
|
2016
Q1 | $108K | Sell |
21,169
-54,512
| -72% | -$356K | ﹤0.01% | 4917 |
|
|
2015
Q4 | $676K | Buy |
75,681
+36,408
| +93% | +$1.31M | ﹤0.01% | 3714 |
|
|
2015
Q3 | $1.5M | Buy |
39,273
+9,192
| +31% | +$454K | ﹤0.01% | 3001 |
|
|
2015
Q2 | $1.39M | Buy |
30,081
+22,909
| +319% | +$918K | ﹤0.01% | 3310 |
|
|
2015
Q1 | $271K | Buy |
7,172
+1,584
| +28% | +$62.9K | ﹤0.01% | 4640 |
|
|
2014
Q4 | $225K | Buy |
+5,588
| New | +$189K | ﹤0.01% | 4930 |
|
Other funds holding CMRX
UBS Group's CMRX Position: Q2 2025 in Review
UBS Group sold out of Chimerix, Inc. (CMRX) in Q2 2025, closing a stake of 2,901,056 shares — an estimated $24.7M sold.
UBS Group first reported a position in CMRX in Q4 2014 and held it in 42 quarters. The position peaked at $24.7M in Q1 2025. 1 fund tracked by Wall St. Rank holds CMRX as of Q2 2025.
- UBS Group reported no remaining Chimerix, Inc. position as of Q2 2025 after selling out during the quarter.
- UBS Group sold 2,901,056 Chimerix, Inc. shares in Q2 2025, an estimated $24.7M.
- UBS Group first reported a position in Chimerix, Inc. in Q4 2014 and held it in 42 quarters.
- UBS Group's Chimerix, Inc. position peaked at $24.7M in Q1 2025.
- 1 fund tracked by Wall St. Rank held Chimerix, Inc. as of Q2 2025.
Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.